Skin Boosters FDA Status: Skinvive vs. Profhilo and US Legal Alternatives

Social media feeds are flooded with testimonials for "skin boosters" like Profhilo, NCTF 135 HA, and Restylane Skinbooster (often referred to as Restylane Vital). These treatments, popular in Europe, Asia, and Latin America, promise to deliver deep hydration, radiant skin texture, and a "lit-from-within" glow by injecting micro-droplets of hyaluronic acid or polyrevitalizing cocktails directly into the superficial dermis.

However, for patients and aesthetic providers in the United States, the regulatory reality is vastly different. While foreign clinics treat skin boosters as standard, everyday offerings, the U.S. Food and Drug Administration (FDA) maintains strict oversight of all injectable substances. Operating, importing, or administering an unapproved injectable device or drug carries substantial legal and health risks.

This guide clarifies today's U.S. regulatory landscape for skin-quality injectables. We analyze the single FDA-approved skin booster (Skinvive by Juvéderm), detail the unapproved status of foreign favorites like Profhilo and NCTF, explain the FDA and Customs and Border Protection (CBP) enforcement mechanisms, map the chemical differences between these products, and outline the legal, US-regulated alternatives available to providers and patients.

---

Which skin boosters are FDA-approved in the United States?

In the United States, any substance injected into the human body for cosmetic remodeling is classified as either a medical device or a drug. Hyaluronic acid-based injectables are regulated as Class III medical devices, which are considered high-risk implants because they are placed into the body and remain there. Class III devices require the most rigorous premarket review path: the Premarket Approval (PMA) pathway, governed by the FDA's Center for Devices and Radiological Health (CDRH).

This is a much higher bar than the standard 510(k) clearance pathway used for energy-based devices. A 510(k) clearance only requires a manufacturer to demonstrate that a new device is "substantially equivalent" to an existing predicate device that is already on the market. In contrast, the PMA pathway requires the manufacturer to independently prove the safety and effectiveness of the device through extensive, prospective, multi-center clinical trials involving human subjects in the United States. These trials must show a statistically significant benefit compared to a control group while documenting any adverse events over a multi-month or multi-year follow-up period. Because of this substantial clinical and financial barrier, many foreign manufacturers choose to skip the U.S. market entirely.

Currently, there is only one skin booster formally approved by the FDA for injection in the United States:

Skinvive by Juvéderm (Allergan Aesthetics)

• FDA Premarket Approval Number: P110033
• Supplement Number: Supplement S059 (Approved May 11, 2023)
• FDA Product Code: LMH (Implant, Dermal, For Aesthetic Use)
• Approved Indication: Microdroplet injection into the intradermal plane of the cheeks to improve skin smoothness in adults aged 21 and older.
• Chemical Formulation (Vycross Technology): Skinvive is formulated using Allergan's proprietary Vycross crosslinking technology. It combines low-molecular-weight and high-molecular-weight hyaluronic acid to create a smooth, highly cohesive gel with a low HA concentration of 12 mg/mL. By minimizing the concentration of HA while maintaining low-density crosslinking with Butanediol Diglycidyl Ether (BDDE), the gel remains highly fluid and distributes evenly when injected intradermally. The crosslinking prevents rapid enzymatic degradation by the body's natural hyaluronidase, allowing the hydrophilic gel to continuously attract moisture and maintain its smoothing effect.
• Longevity: Clinically proven to maintain results and improve skin hydration and elasticity for approximately 6 months per treatment cycle, after which the gel naturally degrades and is absorbed by the body.

Skin-Quality Injectable Classification Matrix (U.S. Market)

[FDA-APPROVED SKIN BOOSTER]
- Skinvive by Juvéderm (P110033 / S059) -> Intradermal HA microdroplet (cheek smoothness, 6-month duration)

[FDA-APPROVED DYNAMIC FILLERS (Used Off-Label for Skin Quality)]
- RHA Redensity (P170002 / S012) -> Superficial dynamic filler (perioral rhytides)
- Belotero Balance (P090016) -> Cohesive polydensified matrix HA filler (superficial lines)

[UNAPPROVED / FOREIGN SKIN BOOSTERS (Absent from FDA PMA Registry)]
- Profhilo (IBSA) -> High-concentration NAHYCO HA bioremodeller (Not FDA-approved)
- Restylane Skinbooster / Vital (Galderma) -> NASHA-based skin booster (Not FDA-approved)
- NCTF 135 HA (Filorga / Fillmed) -> Polyrevitalizing nutrient cocktail (Not FDA-approved)
- Sunekos / Neauvia / Teosyal Redensity 1 -> Meso-infusions & hybrid complexes (Not FDA-approved)

Practitioners must understand that being absent from the FDA’s PMA registry is a definitive marker of non-approval. A search of the FDA’s Premarket Approval (PMA) database and the FDA-Approved Dermal Fillers list returns no entry for Profhilo, Restylane Skinbooster, NCTF, Sunekos, or Neauvia — meaning none has been cleared for legal commercial importation or injection in the United States.

---

Why is Profhilo not FDA-approved, and what does that mean?

Among unapproved skin boosters, Profhilo (manufactured by IBSA, Lodi, Italy) generates the highest volume of consumer and provider search intent. Patients frequently ask: "Is Profhilo available in the U.S.?" and "Why hasn't the FDA approved it?"

The NAHYCO Chemical Mechanism

To understand why Profhilo has not crossed the US regulatory line, it is helpful to look at its chemical composition. Profhilo is not a traditional dermal filler; it is classified as a bioremodeller.

• High Hyaluronic Acid Concentration: Profhilo contains one of the highest concentrations of hyaluronic acid on the market: 64 mg of HA per 2 mL syringe.
• Thermal Hybrid Cooperative Complexes (NAHYCO Technology): Traditional fillers (like Juvéderm Ultra or Restylane) use chemical crosslinking agents—specifically Butanediol Diglycidyl Ether (BDDE)—to bond HA chains together so the body cannot digest them quickly. Profhilo, however, uses no chemical crosslinkers. Instead, IBSA uses a patented thermal process that combines:
  • 32 mg of High-Molecular-Weight HA (1100–1400 kDa)
  • 32 mg of Low-Molecular-Weight HA (80–100 kDa)
• Bioremodelling Action: When heated, these chains form stable hybrid complexes. Once injected using the Bio Aesthetic Points (BAP) technique, the product diffuses smoothly across the subcutaneous and dermal planes. Rather than creating a localized pocket of volume, the hybrid complexes stimulate receptors on keratinocytes and fibroblasts, driving the upregulation of collagens (types I, III, IV, and VII) and elastin (PMC7327616).

Why It Lacks FDA Approval

The absence of FDA approval for Profhilo is primarily a commercial and regulatory strategy decision, not necessarily a clinical safety failure:

1. PMA Clinical Trial Expense: Obtaining PMA approval requires a manufacturer to fund large-scale, multi-center clinical trials within the United States. These trials must compare the product against an active FDA-approved control and track patients over multiple years. For foreign manufacturers with strong market share in Europe and Asia, the cost of these trials may outweigh the projected U.S. revenue.
2. Product Classification: Because Profhilo behaves as a tissue regenerator (bioremodeller) rather than a simple mechanical filler, the FDA’s review path would require complex safety endpoints to prove that the thermal complexes do not trigger unexpected immunogenic reactions or delayed nodules.

Legally, the lack of FDA approval means it is a violation of federal law to import, distribute, or inject Profhilo within the United States. A provider who imports Profhilo (even if purchased from a legitimate European pharmacy) is administering an unapproved medical device. This invalidates malpractice insurance coverage, exposes the provider to state medical board disciplinary action, and constitutes a violation of the Federal Food, Drug, and Cosmetic Act.

---

How does Skinvive differ from Profhilo?

Because Skinvive is the only FDA-approved option, patients and providers frequently compare it directly to Profhilo. However, they are chemically and clinically distinct.

The Clinical Distinction: Microdroplet Filler vs. Bioremodeller

The key difference lies in the crosslinking. Because Skinvive utilizes BDDE crosslinking (albeit at a minimal concentration of 12 mg/mL), it behaves as a highly fluid, long-lasting moisture-retaining grid. The crosslinked HA holds water in the dermis for 6 months before being metabolized.

Profhilo, lacking chemical crosslinking, behaves as a transient signaling molecule. It remains in the tissue for only about 28 days before the thermal complexes degrade, but during that window, it stimulates fibroblasts to deposit new structural proteins. Thus, Skinvive’s effect is primarily hydrophilic hydration, whereas Profhilo’s effect is cellular remodeling.

---

What are the unapproved status details of Restylane Skinbooster and NCTF?

Beyond Profhilo, two other unapproved brands frequently appear in domestic clinical inquiries.

1. Restylane Skinbooster (Restylane Vital / Vital Light)

Manufactured by Galderma, Restylane Skinboosters are based on the company’s proprietary NASHA (Non-Animal Stabilized Hyaluronic Acid) technology.

• The Product: Restylane Vital features a low-concentration, crosslinked HA gel (20 mg/mL) designed for micro-injection.
• The Regulatory Gap: While Galderma holds numerous FDA approvals for its Restylane filler line (such as Restylane-L, Lyft, Silk, Refyne, Defyne, and Kysse), Galderma has never sought FDA approval for the Skinbooster line (Vital or Vital Light) in the United States.
• Clinical Consequence: Because it is not FDA-approved, any Restylane Skinbooster product utilized in a U.S. clinic is an unauthorized import. U.S. providers seeking a similar effect must use approved fillers off-label (explained below) rather than purchasing imported Vital syringes.

2. NCTF 135 HA (New Cellular Treatment Factor)

Originally developed by Filorga (now marketed under the Fillmed brand), NCTF is a "mesotherapy" cocktail.

• The Ingredients: NCTF combines a minimal amount of non-crosslinked hyaluronic acid (5 mg/mL) with a complex mixture of 55 active ingredients, including 12 vitamins, 24 amino acids, 6 coenzymes, 5 nucleic acids, and 4 minerals.
• The Regulatory Gap: NCTF is registered in Europe and Asia as a CE-marked topical or superficial injection product. However, NCTF has zero FDA approvals in the United States.
• The Risk Profile: Because NCTF contains a large number of biological compounds (vitamins, amino acids, minerals), injecting it intradermally carries a high risk of hypersensitivity reactions, contact dermatitis, and delayed-onset granulomas (chronic inflammatory nodules). Without FDA review to establish sterile manufacturing controls and chemical stability, U.S. providers are strictly prohibited from injecting NCTF.

---

What are the legal US alternatives to unapproved skin boosters?

For U.S. providers who refuse to risk their licenses on imported products, or for patients seeking legal, regulated treatments, there are several competitive alternatives that achieve similar skin-quality outcomes.

Legal U.S. Skin-Quality Treatment Pathways

[INTRADERMAL PATHWAY]
- Skinvive by Juvéderm: FDA-approved, intradermal HA, cheek focus.
- Off-Label HA Dilution: Approved cohesive fillers (Belotero, Restylane-L) diluted with saline/lidocaine and injected superficial-dermal.

[DYNAMIC FILLER PATHWAY]
- RHA Redensity: FDA-approved for dynamic lines; highly fluid, works in superficial dermis.

[REGENERATIVE PATHWAY]
- Platelet-Rich Fibrin (PRF): Patient's own autologous growth factors injected microdroplet.
- Microneedling + Topical Actives: Mechanical channel creation paired with FDA-cleared topical serums.

1. Off-Label Dilution of FDA-Approved HA Fillers

A common clinical practice in the United States is the off-label dilution of approved, low-viscosity hyaluronic acid fillers.

• The Technique: Clinicians take highly cohesive, low-viscosity fillers—such as Belotero Balance (P090016) or standard Restylane-L—and dilute them with a sterile mixture of normal saline and preservative-free lidocaine (often in a 1:1 or 1:2 ratio).
• The Application: This diluted HA is then injected in tiny microdroplets into the superficial dermis using a mesotherapy technique.
• Regulatory Context: While the dilution and injection method is off-label, the substance itself (the filler and the saline) is FDA-approved and legally sourced from U.S. distributors. This protects the provider from the legal liabilities associated with importing unapproved foreign devices like Profhilo.

2. RHA Redensity (Teoxane / Revance)

• Core Approval: Approved under PMA P170002/S012 in December 2021.
• Clinical Fit: Redensity is a highly resilient, fluid hyaluronic acid filler cleared for dynamic perioral rhytides (lipstick lines around the mouth). Because it is designed to integrate into areas of high muscle movement without creating lumps, some clinicians utilize it off-label for superficial skin quality and fine line treatment in other facial zones, serving as a close analog to foreign skin boosters.

3. Autologous Platelet-Rich Fibrin (PRF)

• The Technique: The provider draws the patient’s own blood, spins it in a calibrated centrifuge at low speed, and extracts the platelet-rich fibrin layer.
• The Application: PRF is injected in microdroplets into the superficial dermis. Because it is autologous (derived from the patient's own body), there is zero risk of foreign-body granulomas or allergic reactions. The platelets slowly release growth factors (PDGF, TGF-beta, VEGF) over 7–10 days, driving fibroblast activity and tissue remodeling.

---

FDA and CBP Enforcement Against Unapproved Imports

To protect the public from non-sterile and counterfeit injectables, federal agencies actively enforce importation bans. Clinics that purchase unapproved skin boosters online frequently have their shipments seized or receive regulatory warnings.

1. FDA Import Alerts 66-41 and 66-38

The FDA utilizes Import Alerts to identify and detain foreign shipments before they reach U.S. soil.

• Import Alert 66-41 (Detention Without Physical Examination of Unapproved New Drugs): Authorizes U.S. Customs officers to detain any shipment containing unapproved new drugs without physically inspecting them, based on the shipping manifest or the sender's history.
• Import Alert 66-38: Focuses specifically on cosmetics and devices carrying drug claims (such as "skin rejuvenation" or "intradermal injection"). Under these alerts, products like Profhilo, NCTF, and unapproved botulinum toxins are flagged for immediate detention and destruction at the border.

2. U.S. Customs and Border Protection Seizures

Ports of entry with high international mail volumes—such as the CBP facility in Cincinnati, Ohio—regularly release updates regarding the interception of unapproved injectable cosmetics.

• The Risk Profile: Seized shipments frequently originate from online pharmacies in Europe, South Korea, and China. CBP officers working alongside FDA inspectors detain these shipments due to lack of a valid U.S. prescription, lack of PMA/NDA registration, and failure to maintain temperature-controlled shipping environments.
• Lack of Cold Chain Control: Skin boosters are biological and chemical complexes. Shipping them via standard airmail without temperature monitoring degrades the hyaluronic acid and increases the risk of bacterial contamination.

3. The 2025 FDA Warning Letter to Dermax Company

To target the online distribution network that facilitates illegal gray-market imports, the FDA issues Warning Letters to foreign manufacturers and distributors. As part of a November 2025 sweep, the FDA’s Center for Drug Evaluation and Research (CDER) issued Warning Letters to eighteen companies — including a letter dated November 3, 2025 to Dermax Co., Ltd. (China).

The Dermax letter cited the company for operating online portals (including dermaxmed.com) that marketed and sold unapproved and misbranded injectable botulinum toxin products directly to U.S. consumers and clinics, without required prescription oversight. The FDA highlighted that Dermax bypassed the established prescription and drug-authorization pathways, packaging items with labeling that lacked adequate directions for use and failing to verify the credentials of U.S. purchasers. The sweep is a concrete reminder of the FDA's active surveillance of the online injectable supply chain — and a warning to domestic providers that purchasing from these foreign networks violates the Federal Food, Drug, and Cosmetic Act.

4. Other Unapproved Boosters: Sunekos and Neauvia Hydro Deluxe

• Sunekos (Professional Dietetics, Milan, Italy): Sunekos combines non-crosslinked hyaluronic acid with a patented formulation of six essential amino acids (glycine, L-proline, L-lysine, L-alanine, L-valine, and L-leucine). It is marketed for stimulating the extracellular matrix (ECM) to produce both collagen and elastin. While CE-marked in Europe, Sunekos lacks FDA approval and is classified as an unapproved device in the United States.
• Neauvia Hydro Deluxe (Matex Lab, Lugano, Switzerland): Neauvia markets itself as a organic-aligned skin booster, combining non-crosslinked HA (18 mg/mL) with 0.01% calcium hydroxyapatite (CaHA) for additional collagen stimulation. Despite its popularity in South America and parts of Europe, Neauvia has not undergone the FDA Premarket Approval process, and importing the product is prohibited under current import alerts.

---

What are the safety risks of unapproved or imported skin boosters?

Aside from the legal and licensing liabilities, injecting unapproved imports presents severe clinical risks.

Clinical Risk Progression: Imported vs. Regulated Injectables

[UNREGULATED/IMPORTED PRODUCT] (Uncontrolled Cold Chain, Unverified Facility)
  |--> Risk 1: Bacterial Contamination (Sterility failure during transit)
  |--> Risk 2: High Immunogenicity (Foreign proteins or endotoxins in unapproved formulas)
  |--> Risk 3: Delayed Granulomas (Chronic inflammatory nodules forming months post-injection)

[FDA-REGULATED PRODUCT] (Sourced from U.S. Distributor, Validated Sterile Logistics)
  |--> Outcome: Standard transient swelling/bruising; predictable degradation; legal protection

1. Sterility Failure and Infection: FDA-approved injectables are manufactured under strict Current Good Manufacturing Practice (cGMP) standards, and their shipping lines are validated to preserve sterility. Imported skin boosters purchased through gray-market brokers lack this chain of custody. If a shipping box sits in a warm warehouse or on an airport tarmac, the sterile seal can compromise, or the product can degrade, leading to atypical mycobacterial infections that are highly resistant to standard antibiotics.
2. Delayed-Onset Granulomas: Injecting complex cocktails like NCTF or unapproved crosslinked HAVital Vital Light can trigger a delayed immune response. Months after the injection, the body may recognize the unapproved substance as a foreign invader, forming hard, painful inflammatory nodules (granulomas) across the face. Treating these nodules requires repeated injections of corticosteroids or hyaluronidase, which can dissolve the patient's natural tissue.
3. Counterfeit Substitution: Because Profhilo and Restylane Skinboosters carry high brand demand, they are prime targets for counterfeiters. Gray-market packages often contain generic HA or silicone fluids packaged in replica boxes. Injecting industrial-grade silicone or impure HA can lead to permanent disfigurement, tissue necrosis, and blindness if the product accidentally enters a facial blood vessel.

---

Frequently Asked Questions

Is Profhilo FDA-approved or available in the US?

No. Profhilo is not FDA-approved. It is manufactured by IBSA in Italy and is widely available in Europe, Canada, and Asia, but it has not undergone the FDA's Premarket Approval (PMA) pathway. It is illegal to import or inject Profhilo in the United States.

Is Skinvive the same as Profhilo?

No. While both are hyaluronic acid-based skin-quality treatments, they are chemically different. Skinvive (Allergan) is a BDDE-crosslinked hyaluronic acid microdroplet gel cleared for cheek skin smoothness, providing hydration for approximately 6 months. Profhilo (IBSA) is a non-crosslinked bioremodeller that uses thermal hybrid complexes (NAHYCO technology) to stimulate cellular collagen and elastin production, requiring BAP injection points rather than diffuse microdroplets.

Are NCTF, Sunekos, and Restylane Skinbooster FDA-approved?

No. None of these products are FDA-approved for injection in the United States. While manufactured by reputable global companies (such as Galderma for Restylane Skinbooster and Fillmed for NCTF), they lack U.S. Premarket Approvals. Utilizing them in a U.S. clinic violates federal and state regulations.

---

Sources

1. FDA Dermal Fillers Registry: U.S. Food and Drug Administration. FDA-Approved Dermal Fillers. FDA.gov.
2. FDA PMA Database (Skinvive): U.S. Food and Drug Administration. PMA P110033/S059 for Juvéderm Voluma XC / Skinvive.
3. FDA Import Alert Database: U.S. Food and Drug Administration. Import Alert 66-41 — Detention Without Physical Examination of Unapproved New Drugs. Accessdata.fda.gov.
4. CBP Injectable Seizures: U.S. Customs and Border Protection. Cincinnati CBP Intercepts Shipments of Unapproved Injectable Cosmetics. CBP Newsroom.
5. Profhilo Safety and Composition: Sparavigna A, et al. Safety assessment of a hybrid cooperative complex of high and low molecular weight hyaluronic acid (Profhilo) from worldwide postmarketing data. Clinical, Cosmetic and Investigational Dermatology. 2020;13:461-468. PMC7327616.
6. FDA Warning Letter (Dermax): U.S. Food and Drug Administration. Warning Letter to Dermax Co., Ltd.. November 3, 2025. FDA Warning Letters.
7. Skin Boosters Clinical Review: Lipko-Przybylska J, et al. Injectable skin boosters in aging skin rejuvenation: a current overview. Journal of Cosmetic Dermatology. 2024;23(8):2450-2458. PMC11560330.